CME in Minutes: Education in Oncology & Hematology
Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective
12 Jul 2024
Please visit answersincme.com/UYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology and digestive oncology discusses guidance for use of TKI therapy in advanced hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Describe evidence for the optimal use of tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC); Identify patient- and disease-based factors which guide the use of TKI therapy for the treatment of advanced HCC; and Outline strategies to develop personalized treatment plans to maximize clinical outcomes using TKI therapies in the treatment of advanced HCC.
No persons identified in this episode.
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster